JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB275495

Human ACE2 knockout Hep G2 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

ACE2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2.

View Alternative Names

ACE-related carboxypeptidase, ACE2_HUMAN, ACEH, Angiotensin I Converting Enzyme (peptidyl dipeptidase A) 2, Angiotensin I converting enzyme 2, Angiotensin converting enzyme 2, Angiotensin converting enzyme like protein, Angiotensin-converting enzyme homolog, DKFZP434A014, EC 3.4.17, OTTHUMP00000022963, Processed angiotensin-converting enzyme 2, metalloprotease MPROT 15

4 Images
Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)
  • WB

Lab

Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)

Lane 1 : Wild-type HepG2 cell lysate 30 ug
Lane 2 : ACE2 knockout HepG2 cell lysate 30 ug
Lane 3 : Calu-3 cell lysate 30 ug
Lane 4 : A549 cell lysate 30 ug
Lanes 1 - 4 : Merged signal (red and green). Green - ab108209 observed at 130 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab108209 was shown to react with ACE2 in wild-type HepG2 cells in western blot with loss of signal observed in ACE2 knockout cell line ab273733 (knockout cell lysate ab275495). Wild-type and ACE2 knockout HepG2 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab108209 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ACE2 antibody [EPR4436] (<a href='/en-us/products/primary-antibodies/ace2-antibody-epr4436-ab108209'>ab108209</a>) at 1/1000 dilution

Lane 1:

Wild-type HepG2 cell lysate at 30 µg

Lane 2:

ACE2 knockout HepG2 cell lysate at 30 µg

Lane 2:

Western blot - Human ACE2 knockout Hep G2 cell line (<a href='/en-us/products/cell-lines/human-ace2-knockout-hep-g2-cell-line-ab273733'>ab273733</a>)

Lane 3:

Calu-3 cell lysate at 30 µg

Lane 4:

A549 cell lysate at 30 µg

Predicted band size: 92 kDa

Observed band size: 130 kDa

false

Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)
  • WB

Lab

Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)

Lane 1 : Wild-type HepG2 cell lysate 30 ug
Lane 2 : ACE2 knockout HepG2 cell lysate 30 ug
Lane 3 : Calu-3 cell lysate 30 ug
Lane 4 : A549 cell lysate 30 ug
Lanes 1 - 4 : Merged signal (red and green). Green - ab65863 observed at 130 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab65863 was shown to react with ACE2 in wild-type HepG2 cells in western blot with loss of signal observed in ACE2 knockout cell line ab273733 (knockout cell lysate ab275495). Wild-type and ACE2 knockout HepG2 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab65863 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at 1 ug/ml and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ACE2 antibody (<a href='/en-us/products/primary-antibodies/ace2-antibody-ab65863'>ab65863</a>) at 1 µg/mL

Lane 1:

Wild-type HepG2 cell lysate at 30 µg

Lane 2:

ACE2 knockout HepG2 cell lysate at 30 µg

Lane 2:

Western blot - Human ACE2 knockout Hep G2 cell line (<a href='/en-us/products/cell-lines/human-ace2-knockout-hep-g2-cell-line-ab273733'>ab273733</a>)

Lane 3:

Calu-3 cell lysate at 30 µg

Lane 4:

A549 cell lysate at 30 µg

Predicted band size: 92 kDa

Observed band size: 130 kDa

false

Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)
  • WB

Lab

Western blot - Human ACE2 knockout Hep G2 cell lysate (AB275495)

Lane 1 : Wild-type HepG2 cell lysate 30 ug
Lane 2 : ACE2 knockout HepG2 cell lysate 30 ug
Lane 3 : Calu-3 cell lysate 30 ug
Lane 4 : A549 cell lysate 30 ug
Lanes 1 - 4 : Merged signal (red and green). Green - ab108252 observed at 130 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab108252 was shown to react with ACE2 in wild-type HepG2 cells in western blot with loss of signal observed in ACE2 knockout cell line ab273733 (knockout cell lysate ab275495). Wild-type and ACE2 knockout HepG2 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab108252 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ACE2 antibody [EPR4435(2)] (<a href='/en-us/products/primary-antibodies/ace2-antibody-epr44352-ab108252'>ab108252</a>) at 1/1000 dilution

Lane 1:

Wild-type HepG2 cell lysate at 30 µg

Lane 2:

ACE2 knockout HepG2 cell lysate at 30 µg

Lane 3:

Calu-3 cell lysate at 30 µg

Lane 4:

A549 cell lysate at 30 µg

Predicted band size: 92 kDa

Observed band size: 130 kDa

false

Sanger Sequencing - Human ACE2 knockout Hep G2 cell lysate (AB275495)
  • Sanger seq

Lab

Sanger Sequencing - Human ACE2 knockout Hep G2 cell lysate (AB275495)

Allele 1 : 71 bp deletion in exon 2.

Key facts

Cell type

Hep G2

Species or organism

Human

Tissue

Liver

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 71 bp deletion in exon 2

Disease

Hepatocellular Carcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab275495-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human ACE2 knockout Hep G2 cell lysate", "number":"AB275495-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type Hep G2 cell lysate", "number":"AB275495-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
ACE2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The ACE2 protein also known as angiotensin-converting enzyme 2 is an essential component in the renin-angiotensin system. It functions mechanically by converting the hormone angiotensin II to angiotensin-(1-7) which helps regulate blood pressure and fluid balance. The molecular weight of ACE2 is approximately 120 kDa. This protein is expressed in various tissues particularly the lungs heart kidneys and gastrointestinal tract. In cultured cells like Caco-2 cells researchers often study this expression.
Biological function summary

The ACE2 protein plays an important role in the regulation of cardiovascular and renal functions. It is a single-pass type I membrane protein and its activity reduces inflammation and oxidative stress in cells. ACE2 does not function as part of a larger protein complex but its enzymatic conversion has a substantial impact on reducing the effects of angiotensin II in the body leading to vasodilation and decreased blood pressure.

Pathways

ACE2 involvement is significant in the renin-angiotensin system and the kallikrein-kinin system. These pathways are essential for maintaining cardiovascular homeostasis. In the renin-angiotensin system ACE2 works in opposition to angiotensin-converting enzyme (ACE) balancing the effects through the production of angiotensin-(1-7) from angiotensin II. Additionally ACE2 interacts indirectly with proteins like angiotensin receptor type 1 (AT1) and angiotensin receptor type 2 (AT2) ensuring proper signaling and physiological responses.

ACE2 links closely with conditions such as hypertension and COVID-19. Increased activity of angiotensin II due to low ACE2 levels contributes to hypertension. In infectious disease SARS-CoV-2 virus responsible for COVID-19 uses ACE2 as an entry receptor to initiate infection in host cells. This interaction highlights the importance of ACE2 in disease pathogenesis and has prompted interest in ACE2 as a potential therapeutic target.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Proteins & Peptides

AB217407

Recombinant human Vitronectin/S-Protein (Animal Free)

  • 0
  • 0
Primary Antibodies

AB108252

Anti-ACE2 antibody [EPR4435(2)]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ACE2 antibody [EPR4435(2)] (AB108252)

  • 4
  • 10
Assay Kits

AB273297

Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric)

Functional Studies - Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (AB273297)

  • 3
  • 2
Assay Kits

AB235649

Human ACE2 ELISA Kit

Recombinant|SimpleStep

ELISA - Human ACE2 ELISA Kit (AB235649)

  • 5
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com